- Home
- ANTX vs RNTX Comparison
ANTX vs RNTX Comparison
Compare ANTX & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- RNTX
- Stock Information
- Founded
- ANTX 2017
- RNTX 2001
- Country
- ANTX United States
- RNTX United States
- Employees
- ANTX N/A
- RNTX N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- RNTX Health Care
- Exchange
- ANTX Nasdaq
- RNTX Nasdaq
- Market Cap
- ANTX 37.6M
- RNTX 44.2M
- IPO Year
- ANTX 2022
- RNTX N/A
- Fundamental
- Price
- ANTX $1.41
- RNTX $2.02
- Analyst Decision
- ANTX Hold
- RNTX
- Analyst Count
- ANTX 5
- RNTX 0
- Target Price
- ANTX $3.50
- RNTX N/A
- AVG Volume (30 Days)
- ANTX 168.1K
- RNTX 48.0K
- Earning Date
- ANTX 03-27-2025
- RNTX 04-14-2025
- Dividend Yield
- ANTX N/A
- RNTX N/A
- EPS Growth
- ANTX N/A
- RNTX N/A
- EPS
- ANTX N/A
- RNTX N/A
- Revenue
- ANTX N/A
- RNTX N/A
- Revenue This Year
- ANTX N/A
- RNTX N/A
- Revenue Next Year
- ANTX N/A
- RNTX N/A
- P/E Ratio
- ANTX N/A
- RNTX N/A
- Revenue Growth
- ANTX N/A
- RNTX N/A
- 52 Week Low
- ANTX $0.87
- RNTX $1.61
- 52 Week High
- ANTX $3.88
- RNTX $7.42
- Technical
- Relative Strength Index (RSI)
- ANTX 72.16
- RNTX N/A
- Support Level
- ANTX $1.09
- RNTX N/A
- Resistance Level
- ANTX $1.39
- RNTX N/A
- Average True Range (ATR)
- ANTX 0.06
- RNTX 0.00
- MACD
- ANTX 0.03
- RNTX 0.00
- Stochastic Oscillator
- ANTX 94.20
- RNTX 0.00
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.